Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

Author(s):

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago

This episode covers current sequencing strategies for NSCLC after targeted therapies and platinum chemotherapy, discusses the COMPEL trial with osimertinib, reviews OS and PFS end points from the TROPION-Lung01 study, examines hypotheses behind differential PFS responses in nonsquamous vs squamous NSCLC, and addresses what constitutes a clinically meaningful, durable response in heavily pretreated patients with advanced NSCLC and actionable genomic alterations.

EP: 1.Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP: 2.Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP: 3.ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP: 4.Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP: 5.Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP: 6.Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

Now Viewing

EP: 7.Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP: 8.Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

EP: 9.Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

EP: 10.Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP: 11.Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

EP: 12.Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

EP: 13.Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02

EP: 14.Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

Video content above is prompted by the following:

What are your current sequencing strategies for after getting AGA, after getting approved targeted therapies, and after getting platinum chemotherapy?
Please discuss the COMPEL trial results with osimertinib.
Tell us about the OS and PFS end points of the TROPION-Lung01 study.
What are some prevailing hypotheses that might explain the apparent differential PFS response and positive trend in OS with Dato-DXd among patients with nonsquamous vs squamous NSCLC histology?
In your professional opinion, what length of time constitutes a clinically meaningful, durable response among heavily pretreated patients with advanced or metastatic NSCLC and actionable genomic alterations?